TR-1: Standard form for notification of major holdings

1. Issuer Details
ISIN
GB00BL6K5J42
Issuer Name
ENDEAVOUR MINING PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Van Eck Associates Corporation
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States
4. Details of the shareholder

Name City of registered office Country of registered office
VanEck Gold Miners UCITS ETF    
VanEck Africa Index ETF    
VanEck Gold Miners ETF    
VanEck Gold Miners ETF AU    
VanEck Junior Gold Miners ETF    
VanEck Junior Gold Miners UCITS ETF    
VanEck MSCI International Quality ETF    
VanEck Natural Resources ETF    
VanEck S&P Global Mining UCITS ETF    

5. Date on which the threshold was crossed or reached
21-Sep-2026
6. Date on which Issuer notified
23-Sep-2026
7. Total positions of person(s) subject to the notification obligation

. % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached 7.000580 0.000000 7.000580 16917283
Position of previous notification (if applicable) 6.975666 0.000000 6.975666  

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1)
GB00BL6K5J42 16917283   7.000580  
Sub Total 8.A 16917283 7.000580%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights
         
Sub Total 8.B1      

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights
           
Sub Total 8.B2      

9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Van Eck Associates Corporation VanEck Gold Miners ETF 2.440480   2.440480%
Van Eck Associates Corporation VanEck Natural Resources ETF 0.004850   0.004850%
Van Eck Associates Corporation VanEck Gold Miners ETF AU 0.098340   0.098340%
Van Eck Associates Corporation VanEck Gold Miners UCITS ETF 0.387910   0.387910%
Van Eck Associates Corporation VanEck Africa Index ETF 0.023980   0.023980%
Van Eck Associates Corporation VanEck Junior Gold Miners ETF 3.420980   3.420980%
Van Eck Associates Corporation VanEck S&P Global Mining UCITS ETF 0.098780   0.098780%
Van Eck Associates Corporation VanEck Junior Gold Miners UCITS ETF 0.510350   0.510350%
Van Eck Associates Corporation VanEck MSCI International Quality ETF 0.014870   0.014870%

10. In case of proxy voting
Name of the proxy holder
Glass Lewis
The number and % of voting rights held
16,917,283 shares and 7.00% voting rights
The date until which the voting rights will be held

If date does not apply, explain below
Open
11. Additional Information
Correction of a previous notification, specifically correcting the number of shares in section 10
12. Date of Completion
24-Sep-2026
13. Place Of Completion
Tampa, FL, USA

Attachment

Press release

Montrouge, September 25th, 2026

End of Crédit Agricole S.A.’s share repurchase program

Crédit Agricole S.A.’s share repurchase program, which started on 10 August 2026, was fully completed on 23 September 2026.

As of 23 September 2026, 31,999,995 shares of Crédit Agricole S.A. have been purchased pursuant to the irrevocable instruction given to an independent investment services provider, for an aggregate purchase price of 605,540,453 euros. Such irrevocable instruction was therefore terminated as of the same date.

As previously announced, this transaction aims at offsetting the dilutive effect of the 2026 capital increase reserved for employees, and the shares purchased in the context of this share repurchase program will be cancelled.

This transaction’s impact on Crédit Agricole S.A.’s CET1 ratio is -14 basis points, and -9 basis points on Crédit Agricole group’s one.

Execution of the existing liquidity agreement with Kepler Cheuvreux was temporarily suspended during the execution of the share repurchase program and will resume.

Crédit Agricole S.A. press contacts
Alexandre Barat: 06 19 73 60 28 – alexandre.barat@credit-agricole-sa.fr
Olivier Tassain: 06 75 90 26 66 – olivier.tassain@credit-agricole-sa.fr

All our press releases can be found at: https://www.credit-agricole.com/en

        @Credit_Agricole            Groupe Crédit Agricole

Attachment

Octopus Titan VCT plc

Half-Yearly Report

Octopus Titan VCT plc announces the half-yearly report for the six months ended 30 June 2026.

Titan’s mission is to invest in the people, ideas and industries that will change the world.

Octopus Titan VCT plc (‘Titan’ or the ‘Company’) is managed by Octopus AIF Management Limited (the ‘Manager’), which has delegated investment management to Octopus Investments Limited (‘Octopus’ or the ‘Portfolio Manager’) via its investment team Octopus Ventures.

Key financials

  HY2026 HY2025 FY2025
Net assets (£’000) £742,726  £786,495  £732,844 
Profit/(loss) after tax (£’000) £9,663 £(36,884) £(90,535)
NAV per share 45.1p 47.7p 44.5p
Total value per share1 150.7p 153.3p 150.1p
Total return per share2 0.6p (2.3)p (5.5)p
Total return per share %3 1.3% (4.6)% (10.9)%
Dividends paid in the period Nil 0.5p 0.5p
Dividend yield %4 0.0% 1.0% 1.0%
Dividend declared 1.0p Nil Nil
  1. Total value per share is an alternative performance measure, calculated as NAV plus cumulative dividends paid since launch.
  2. Total return per share is an alternative performance measure, calculated as movement in NAV per share in the period plus dividends paid in the period.
  3. Total return % is an alternative performance measure, calculated as total return/opening NAV.
  4. Dividend yield is an alternative performance measure, calculated as dividends paid/opening NAV.

Interim Management Report

Chair’s statement

Titan’s total return for the six months to 30 June 2026 was 1.3%, with net assets at the period end totalling £743 million.

The Net Asset Value (NAV) per share at 30 June 2026 was 45.1p, compared with 44.5p at 31 December 2025. No dividends were paid during the period, resulting in a total return of 1.3%.

After a prolonged period of declining NAV, it is encouraging to report a modest increase in the first six months of the year. The Board, however, remains cautious. Performance remains materially below the levels we are seeking to achieve over the longer term and a modest improvement over a single six-month period does not constitute a recovery.

Underlying portfolio valuation movements were mixed. A number of companies delivered positive operational progress and valuation increases, while others continued to experience trading, funding or market-related pressures. Encouragingly, the number and value of write-offs and disposals at minimal or nil value have fallen materially. As shareholders will recall, these items caused much of the NAV decline in 2025. More detail on the principal movements in the portfolio is set out in the Portfolio Manager’s review.

Furthermore, there has been a significant improvement in realisation activity during the period, with the Company receiving disposal proceeds of £45.5 million compared with only £6.5 million in the whole of 2025. This represents welcome progress against one of the priorities identified through the Strategic Review, although further improvement is required if Titan is to meet its longer-term objective for realisations to support dividends, operating costs and a proportion of share buybacks sustainably. This objective is not yet being achieved.

Despite the modest increase in NAV during the period, longer-term investment performance remains disappointing. Titan’s one-year total return was -2.6p (-5.5%), five-year total return was -47.2p (-41.4%) and ten-year total return was -4.0p (-4.2%).

In the six months to 30 June 2026, the Company utilised £11.9 million of its cash resources, comprising £3.9 million in investments and £8.0 million in management fees and other running costs. No dividends were paid and no share buybacks were undertaken during the period.

Cash and corporate bonds totalled £190 million at 30 June 2026, representing 26% of net assets, compared with £154 million and 21% respectively at 31 December 2025.

Objectives, guardrails and oversight
The Board continues to monitor progress against the agreed objectives and guardrails established as part of the Strategic Review. These provide defined measures against which the Company’s performance and progress towards a more sustainable position are assessed. For the period ended 30 June 2026, the Company has not met its guardrail metrics and Titan therefore remains within its Transition Period. The Board continues to look for sustained evidence of improved investment performance and realisations before concluding that the Company is operating at, or close to, a sustainable level.

As part of the Board’s ongoing oversight of the portfolio, it held a dedicated strategy session during the period with the Portfolio Manager. Recognising the importance of the existing portfolio to delivering improved returns and realisations, the session considered in detail the prospects of individual portfolio companies and potential pathways to value creation and liquidity.

The Portfolio First strategy has also continued to concentrate resources and capital on supporting the existing portfolio, strengthening operational performance and progressing opportunities for cash realisations.

The progress during the first half is welcome, but it remains too early to draw firm conclusions. Further improvements will be required and the Board will continue to monitor performance closely against the framework established through the Strategic Review.

The revised fee arrangements introduced following the Strategic Review also remain in place, including the mechanism under which Octopus may rebate a proportion of its annual management fee during the Transition Period if the agreed performance and realisation requirements are not achieved.

While any rebate is determined based on performance over the full year, the half-yearly results reflect the Board’s current expectation of the rebate that may become payable for 2026.

Dividends
In determining dividend payments, the Board carefully considers NAV performance, the level and timing of cash realisations, available cash, distributable reserves and the Company’s continued compliance with VCT regulations, including the requirement for at least 80% of relevant holdings to be invested in VCT qualifying investments. The Board also fully recognises the importance that shareholders place on tax-free dividends.

Having considered these factors, together with the Company’s forecast cash position at 31 December 2026, the Board has declared an interim dividend of 1.0 pence per share, payable on 18 December to shareholders on the register on 4 December. The dividend will result in a cash payment of approximately £16.5 million.

Based on current forecasts, following payment the Company is expected to remain above the Board’s target cash guardrail, while the dividend will also increase headroom above the minimum VCT qualifying holdings requirement. No Dividend Reinvestment Scheme (DRIS) will operate in respect of this dividend.

The Board believes that a dividend represents an appropriate use of the Company’s available capital at this stage, providing a return of cash across the shareholder base while supporting the management of the Company’s VCT qualifying position. However, improving NAV performance remains a key priority. While cash realisations improved significantly during the period, the proposed dividend exceeds the total return generated during the first half of the year and the level of distribution has therefore been set in the context of current performance, alongside the Company’s liquidity and VCT requirements.

Titan remains within its Transition Period and continues to operate outside the agreed guardrails for investment performance and realisations, while also remaining below its sustainability Alternative Performance Measure (APM) target. The declaration of this dividend does not represent a change in the Board’s assessment of the Company’s underlying performance, nor a current intention to return to a regular level of distributions.

The Board continues to monitor the interaction between performance, realisations, liquidity, distributable reserves, the agreed guardrails and the Company’s VCT qualifying position. These factors can change over time and need to be considered collectively when determining the appropriate level of distributions. The Board will review the position again as part of the full-year accounts process, including whether a further distribution would be appropriate at that time.

Share buybacks
The Board also recognises the importance that shareholders place on having access to liquidity in their shares.

No share buybacks were undertaken during the period. As set out following the Strategic Review, the ability to conduct buybacks during the Transition Period is dependent on the Company’s overall performance, liquidity position, realisations, distributable reserves and continued compliance with VCT and other regulatory requirements.

Although there has been progress during the period, the Board believes it remains appropriate to maintain a disciplined approach to the use of capital while the Company remains in the Transition Period.

Additionally, Titan’s shares continue to trade in the secondary market at a significant discount to the last reported NAV. Under the current authorities and pricing constraints, this means the Company is unable to conduct buybacks in a manner that is both compliant and fair to shareholders.

The Board remains mindful of the importance of the buyback facility in providing liquidity for shareholders and will keep the potential reintroduction of share buybacks under review.

Principal risks and uncertainties
The Board continues to review the principal risks facing the Company on a regular basis.

The principal risks and uncertainties described on pages 42 to 45 of the 2025 Annual Report remain relevant.

Market conditions for private venture-backed companies continue to be challenging. While there have been some signs of improvement in venture investment activity, fundraising and exit activity remain subdued, with realisations concentrated among a relatively small number of companies.

Public equity markets proved relatively resilient during the period. However, valuation multiples for listed companies in sectors relevant to Titan’s portfolio, particularly software, remained under pressure. As these public market multiples can provide relevant benchmarks when valuing comparable private companies, this continues to influence valuations across parts of Titan’s portfolio. Against this backdrop, the portfolio remains exposed to risks including funding availability, valuation movements, company-specific execution, foreign exchange movements and the timing and value of realisations.

The Board and Portfolio Manager continue to monitor these risks closely.

Board of Directors
As part of the Board’s ongoing succession planning, and taking account of shareholder sentiment, I have informed the Board of my intention to step down as Chair of the Company. Having joined the Board in 2018 as a Non-Executive Director, served as Chair of the Audit Committee from June 2021, and subsequently been appointed Chair of the Board in 2022, I believe it is now the appropriate time to begin the process of appointing my successor. A search will commence for an external Chair, and on appointment of the new Chair, I will retire from the Board.

Lord Rockley has also indicated his intention to step down from the Board. Lord Rockley has made a significant contribution to the Company over his 5 years as Chair of the Audit Committee and will remain in post while the Board progresses its succession plans, helping to ensure an orderly transition and continuity of experience.

A structured recruitment process will now commence for a new independent Non-Executive Chair, and an additional independent Non-Executive Director.

The Board is conscious of the importance of maintaining continuity and appropriate skillset and experience during a period of change for the Company. We also recognise the importance of ensuring the Board continues to evolve as Titan progresses through its Transition Period. The phased approach to these appointments is intended to provide an orderly handover while ensuring the Board continues to have the appropriate balance of skills, experience and independence to oversee the Company.

Annual General Meeting (AGM)
At the AGM held in June, all resolutions were passed by way of a poll. However, the resolutions for the approval of the Directors’ Remuneration Policy and Remuneration Report and the re-election of all Directors (resolutions 2 to 8 respectively) received more than 20% of votes against. In accordance with the AIC Code of Corporate Governance, the Board has contacted the relevant shareholders to understand their reasons for voting against.

The responses received were broadly consistent and primarily related to the Company’s disappointing investment performance. The Board recognises these concerns and hopes that the actions taken following the Strategic Review, together with the ongoing monitoring of progress against the agreed guardrails and the early progress reported during the period, provide shareholders with some reassurance that clear measures are in place against which the Company’s progress can be assessed.

Alongside our formal shareholder engagement, the Board again commissioned an independent shareholder survey during the period. The level of participation from shareholders and independent financial advisers was the highest in the Company’s research to date.

The findings showed broad support for the principal changes arising from the Strategic Review, particularly the revised fee structure and the focus on maximising value from the existing portfolio. At the same time, shareholders and financial advisers were clear that improved investment performance remains the principal measure by which progress will ultimately be judged.

The Board agrees with that assessment and will continue to communicate openly on progress.

Outlook
At the end of the previous financial year, the Board said that the period ahead needed to demonstrate tangible progress through, as a minimum, greater stability in NAV, an improvement in realisation activity and evidence of stronger operational performance within portfolio companies.

The first six months of the year have shown some movement in the right direction. NAV has increased modestly and the level of cash realisations has improved substantially. A number of companies in the portfolio are also demonstrating encouraging operational progress.

However, there remains considerable work to do. The Company has not yet met its agreed guardrails, performance over recent years remains disappointing and conditions across venture markets continue to be fairly challenging. The timing and value of future realisations also remain inherently uncertain.

The Board will therefore maintain the disciplined approach established through the Strategic Review. The immediate priorities remain to protect and build value within the existing portfolio, direct capital selectively towards those companies which have the potential to generate the greatest return, and continue to progress credible opportunities for realisation.

Tom Leader
Chair

Portfolio Manager’s review
Following the Strategic Review, our priority remains the Portfolio First strategy: focusing our time and Titan’s capital on supporting the existing portfolio and maximising long-term value for shareholders. During the first half of 2026, this has meant a selective approach to further investment, alongside an increased focus on portfolio performance and opportunities for realisation.

Focus on performance
The NAV per share at 30 June 2026 was 45.1p, compared with 44.5p at 31 December 2025, representing a total return of 1.3% for the six months ended 30 June 2026.

The performance over the five years to 30 June 2026 is shown below:

  Year ended 31 December 2021 Year ended 31 December 2022 Year ended 31 December 2023 Year ended 31 December 2024 Year ended 31 December 2025 Six months ended 30 June 2026
NAV (p) 105.7 76.9 62.4 50.5 44.5 45.1
Cumulative dividends paid (p) 92.0 97.0 102.0 105.1 105.6 105.6
Total value (p) 197.7 173.9 164.4 155.6 150.1 150.7
Total return1 20.3% (22.5)% (12.4)% (14.1)% (10.9)% 1.3%
Dividend yield2 11.3% 4.7% 6.5% 5.0% 1.0% 0.0%

1. Total return % is an alternative performance measure, calculated as total return/opening NAV.
2. Dividend yield is an alternative performance measure, calculated as dividends paid/opening NAV.

The increase in NAV was supported by positive net valuation movements across 40 companies, which collectively increased the value of the portfolio by £49.8 million. The largest positive contributors to NAV were XYZ Reality, Pelago and Quantum Motion Technologies (QMT). These movements were principally driven by strong revenue growth and commercial performance, as well as improved funding prospects at XYZ Reality. This positive underlying performance more than offset the impact of lower market valuation multiples at some companies.

These gains were partially offset by downward valuation movements across 42 companies, which collectively reduced the value of the portfolio by £42.5 million. The largest negative contributors to NAV were Amplience, Many Group and Vitesse. These movements were principally driven by lower market valuation multiples and more cautious valuation assumptions. This was despite strong commercial progress at some of these businesses, including improved profitability or recurring revenue growth.

The remaining companies experienced no net valuation movement during the period. This includes companies held at nil value and businesses where the available valuation evidence supported maintaining the previous carrying value.

Overall, these movements resulted in a net positive valuation movement of £7.2 million across the portfolio, excluding foreign exchange movements.

The gain on Titan’s uninvested cash reserves was £2.7 million in the six months to 30 June 2026, primarily driven by a return of £3.2 million on the money market funds and bond coupon income, and a fair value movement of £(0.5) million in the corporate bond portfolio. The objective for the money market funds is to earn appropriate market rates on highly liquid treasury holdings, with limited risk to capital.

Disposals
During the six months to 30 June 2026, the Company received £45.5 million in cash and deferred proceeds from portfolio realisations, representing a significant improvement on the level achieved in the previous full year alone. These exits generated a gain of £7.1 million recognised in the income statement during the period.

Generating cash from the existing portfolio remains an important focus under the Portfolio First strategy. We continue to dedicate significant resource to progressing potential realisations, both through full exits and opportunities to realise part of the Company’s investment where we believe this is in shareholders’ interests.

While the improvement in realisation activity during the period is encouraging, further progress is required and the timing and value of future exits remain inherently uncertain.

Full exits
During the period, Flock, a commercial motor insurance business, was acquired by Admiral. The transaction resulted in the full disposal of Titan’s investment, generating proceeds of £9.0 million. The sale contributed to the improvement in realisation activity during the period, an important focus of the Portfolio First strategy.

Partial exits
Titan has also generated £34.9 million through two partial realisations, while allowing the Company to retain exposure to the future performance of both businesses. Partial realisations are an important part of our approach to generating liquidity from the portfolio. The team actively assesses opportunities to realise part of Titan’s holdings where we believe this can generate attractive proceeds for the Company while retaining exposure to potential future value.

Exits at a loss and placed into administration
In March, Inflow was acquired by Cerebral, a US-based mental healthcare provider. The transaction was completed through an exchange of shares, meaning the Company received shares in Cerebral in place of its holding in Inflow.

Also in March, the Company exited its investment in Elo Health with no capital returned.

Unfortunately, Haiper, Smiler and Orbex Space were placed into administration during the period. In aggregate, Titan’s original investment cost in these companies was £20.3 million. At 31 December 2025, they were collectively valued at £nil.

The companies had been unsuccessful in securing sufficient further funding and had explored the available alternatives before entering administration.

During the six months, Origami Energy, All Plants and GTN were also fully dissolved, having exited the portfolio following administration in previous reporting periods.

The failure of a portfolio company is always disappointing for Octopus and shareholders alike, but it is an inherent characteristic of venture capital investing. We expect successful realisations to outweigh losses over the medium to long term.

Deferred proceeds
During the six months, Titan also received £1.6 million of deferred proceeds relating to companies disposed of in previous reporting periods. These included proceeds relating to Papercup (to Scale AI in 2025) and Cobee (to Pluxee in 2024).

VCT qualifying status
Shoosmiths LLP provides both the Board and Octopus with advice concerning ongoing compliance with HMRC rules and regulations relating to VCTs and has advised that Titan continues to comply with the conditions set by HMRC for maintaining approval as a VCT.

In particular, as at 30 June 2026, 84% of the portfolio, as measured under HMRC rules, was invested in VCT-qualifying investments, above the 80% current VCT-qualifying threshold. This threshold is continually monitored both internally by the Manager and by external advisers, and proactive measures are taken to maintain compliance.

  Year ended 31 December 2021 Year ended 31 December 2022 Year ended 31 December 2023 Year ended 31 December 2024 Year ended 31 December 2025 Six months ended
30 June
2026
Total
Disposal proceeds1 (£’000) 221,504 62,213 45,637 41,432 6,510 45,549 422,845

1. This table includes cash and deferred proceeds received in the period.

Portfolio First strategy
Following the Strategic Review, Titan remains in its Transition Period and we continue to operate the Portfolio First strategy which has been in place since mid-2024.

Our principal focus is on maximising value from the existing portfolio. Given Titan’s position, we believe the best path to value recovery is through focusing on existing holdings. Our resources are therefore concentrated on supporting portfolio companies to improve their operational performance, strengthen their financial position and, where appropriate, prepare for future liquidity events.

This means taking an increasingly selective approach to the deployment of further capital. We assess both the potential return from providing additional funding and the opportunity cost of committing Titan’s capital when deciding whether to participate in a portfolio company’s funding round.

We have also continued to strengthen the resources dedicated to portfolio optimisation, with greater focus on identifying and preparing companies for potential exits and other liquidity events. We have also continued to support portfolio companies through our dedicated People and Talent team, working with founders and leadership teams on areas including leadership development, senior recruitment and organisational design.

New and follow-on investments
One investment classified as a new investment for reporting purposes was made during the six months to 30 June 2026. This represented the second tranche of Titan’s existing investment in RemoFirst, which was originally committed to in 2024, before the Company adopted its Portfolio First strategy. No investments in new portfolio companies were made during the period.

Titan invested £2.7 million across three follow-on investments in existing portfolio companies during the period. These included further investment in Living Optics, Puraffinity and AgileRL. Follow-on investment remains selective and is considered where we believe additional capital can protect or enhance Titan’s existing position and offers an appropriate potential return for shareholders.

There were also a number of funding rounds completed by portfolio companies in which Titan chose not to participate. This reflects the Portfolio First strategy and the greater discipline now being applied to capital allocation. Choosing not to participate does not necessarily indicate a negative view of a company; rather, each decision considers the full context of Titan’s objectives.

Valuations
Titan’s unquoted portfolio companies are valued in accordance with UK GAAP accounting standards and the International Private Equity and Venture Capital (IPEV) valuation guidelines.

This means we value the portfolio at fair value, which is the price we expect people would be willing to buy or sell an asset for, assuming they had all the information available that we do, are knowledgeable parties with no pre-existing relationship, and that the transaction is carried out under the normal course of business.

‘External price’ includes valuations based on funding rounds that were typically completed by the reporting date or shortly after the period end, and exits of companies where terms have been issued with an acquirer. ‘Multiples’ is predominantly used for valuations that are based on a multiple of revenues for portfolio companies. Where there is uncertainty around the potential outcomes available to a company, a probability-weighted ‘scenario analysis’ is considered.

‘Milestone analysis’ is used for very early-stage investments that are not yet generating revenue. The initial value is estimated by starting with the price from the most recent funding round. This is then adjusted based on the company’s progress against qualitative milestones, such as product development, customer growth, or regulatory approvals, to reflect any increase or decrease in value.

For companies with multiple business segments or revenue streams, we may value each component separately to reflect the differing characteristics and economics of the underlying activities. The resulting component values are then combined to determine the overall fair value of the business.

Valuation methodology by value:

  • Multiples: 60%
  • External price: 25%
  • Milestone analysis: 9%
  • Scenario analysis: 6%

Valuation methodology by number of companies:

  • Multiples: 28
  • External price: 22
  • Milestone analysis: 16
  • Scenario analysis: 25
  • Write off: 36

Top 20

The top 20 holdings represented 69% of Titan’s portfolio value at 30 June 2026.

The concentration of value within Titan’s largest holdings means that the performance of these companies will continue to have a significant influence on overall shareholder returns. Supporting these businesses to build value and, where appropriate, progress towards successful realisations therefore remains a central part of the Portfolio First strategy.

  Portfolio Investment focus Investment cost Total valuation including cost Value multiple1
1 Skin+Me Health £11.5m £43.2m 3.8x
2 Pelago Health £17.9m £31.1m 1.7x
3 Elliptic Fintech £9.0m £29.2m 3.2x
4 vHive Deep tech £8.0m £27.7m 3.5x
5 ManyPets Fintech £10.0m £23.8m 2.4x
6 Vitesse Fintech £8.8m £23.4m 2.7x
7 Amplience B2B software £12.4m £23.1m 1.9x
8 Permutive B2B software £19.0m £19.7m 1.0x
9 Legl B2B software £7.3m £17.2m 2.4x
10 Token Fintech £13.6m £16.1m 1.2x
11 RemoFirst Fintech £6.2m £15.4m 2.5x
12 Automata Health £14.3m £14.1m 1.0x
13 Bondaval Fintech £7.1m £13.4m 1.9x
14 Quantum Motion Deep tech £5.1m £12.4m 2.4x
15 Ometria B2B software £11.5m £11.5m 1.0x
16 Voy2 Health £2.1m £11.4m 5.4x
17 Intropic Fintech £8.4m £11.1m 1.3x
18 Taster Consumer £8.1m £11.1m 1.4x
19 CoMind Deep tech £7.9m £10.8m 1.4x
20 Seatfrog Consumer £9.6m £10.0m 1.0x

1. The value multiple is calculated by dividing the current valuation by the investment cost.
2. Menwell Limited (trading as Voy, formerly Manual).

Outlook

There were some encouraging developments during the first half of 2026, although progress remains modest and much more still needs to be done.

Global venture investment and exit values have shown signs of improvement, although activity remains concentrated in a relatively small number of larger transactions and businesses associated with AI. Funding conditions for many other venture-backed companies remain challenging, while valuation multiples for publicly listed software companies, which can provide relevant benchmarks for valuing comparable companies in Titan’s portfolio, have remained under pressure.

Against this backdrop, we remain focused on the areas within our control.

The Portfolio First strategy means concentrating our time and capital on those existing portfolio companies where we believe there is the greatest potential to create and realise value. This includes working with management teams to improve operational performance and capital efficiency, supporting appropriate funding rounds selectively and preparing companies for liquidity events where market conditions and company performance make this possible.

The improvement in realisation activity during the first half is encouraging versus the previous year, and demonstrates that liquidity can be generated from the portfolio even in a selective exit environment. However, the timing of individual transactions remains inherently uncertain and further realisations are required.

Similarly, the modest improvement in NAV is welcomed after several years of declining performance, but it is too early to conclude that this represents a durable change in trajectory.

Our focus for the remainder of the year therefore remains unchanged: to improve performance across the existing portfolio, exercise discipline in the deployment of Titan’s capital and pursue opportunities to realise value for shareholders.

Rebuilding shareholder confidence will require sustained delivery over time and we remain focused on making progress against the objectives established following the Strategic Review.

Directors’ responsibilities statement

The Directors confirm that to the best of their knowledge:

  • the half-yearly financial statements have been prepared in accordance with ‘Financial Reporting Standard 104: Interim Financial Reporting’ issued by the Financial Reporting Council;
  • the half-yearly financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company; and
  • the half-yearly report includes a fair review of the information required by the Financial Conduct Authority Disclosure Guidance and Transparency Rules, being:
    • we have disclosed an indication of the important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;
    • we have disclosed a description of the principal risks and uncertainties for the remaining six months of the year; and
    • we have disclosed a description of related party transactions that have taken place in the first six months of the current financial year, that may have materially affected the financial position or performance of the Company during that period, and any changes in the related party transactions described in the last annual report that could do so.

By Order of the Board

Tom Leader 
Chair

Income statement

  Unaudited Unaudited Audited
  Six months to 30 June 2026 Six months to 30 June 2025 Year to 31 December 2025
  Revenue Capital Total Revenue Capital Total Revenue Capital Total
  £’000 £’000 £’000 £’000 £’000 £’000 £’000 £’000 £’000
Gain/(loss) on disposal of fixed asset investments –  7,077  7,077  –  1,184  1,184  –  (5,227) (5,227)
Gain/(loss) on disposal of current asset investments –  5  5  –  105  105  –  (15) (15)
Gain/(loss) on valuation of fixed asset investments –  7,245  7,245  –  (29,593) (29,593) –  (72,727) (72,727)
(Loss)/gain on valuation of current asset investments –  (440) (440) –  1,450  1,450  –  (145) (145)
Investment income 3,180  –  3,180  1,503  –  1,503  8,074  –  8,074 
Investment management fee (300) (5,706) (6,006) (413) (7,838) (8,251) (750) (14,253) (15,003)
Other expenses (1,397) –  (1,397) (3,324) –  (3,324) (5,464) –  (5,464)
Foreign exchange translation –  (1) (1) –  42  42  –  (28) (28)
Proft/(loss) before tax 1,483  8,180  9,663  (2,234) (34,650) (36,884) 1,860  (92,395) (90,535)
Tax –  –  –  –  –  –  –  –  – 
Proft/(loss) after tax 1,483  8,180  9,663  (2,234) (34,650) (36,884) 1,860  (92,395) (90,535)
Proft/(loss) per share – basic and diluted 0.1p 0.5p 0.6p (0.1)p (2.1)p (2.2)p 0.1p (5.6)p (5.5)p
  • The ‘Total’ column of this statement is the profit and loss account of the Company; the supplementary revenue return and capital return columns have been prepared under guidance published by the Association of Investment Companies.
  • All revenue and capital items in the above statement derive from continuing operations.
  • Titan has only one class of business and derives its income from investments made in shares and securities and from bank and money market funds.

Titan has no other comprehensive income for the period.

The accompanying notes form an integral part of the financial statements.

Balance sheet

  Unaudited Unaudited Audited
  As at 30 June 2026 As at 30 June 2025 As at 31 December 2025
  £’000 £’000  £’000  £’000  £’000 £’000  
Fixed asset investments   546,284    620,190    573,410 
Debtors: amounts falling due after more than one year   3,190    –   3,597 
Current assets:            
Money market funds 134,629    75,328    75,018   
Corporate bonds 53,381    84,569    77,809   
Applications cash1 20    18    18   
Cash at bank 2,232    918    806   
Debtors: amounts falling due within one year 3,553    6,280    3,447   
    193,815    167,113    157,098 
Creditors: amounts falling due within one year (563)   (808)   (1,261)  
Net current assets   193,252    166,305    155,837 
Net assets   742,726    786,495    732,844 
Share capital   1,648    1,647    1,648 
Share premium   475    257    256 
Capital redemption reserve   141    141    141 
Special distributable reserve   1,048,301    1,048,301    1,048,301 
Capital reserve realised   (221,111)   (149,705)   (241,857)
Capital reserve unrealised   (45,804)   (67,716)   (33,239)
Revenue reserve   (40,924)   (46,430)   (42,406)
Total equity shareholders’ funds   742,726    786,495    732,844 
NAV per share   45.1p   47.7p   44.5p

1. Cash held but not yet allotted.

The accompanying notes form an integral part of the financial statements.

The statements were approved by the Directors and authorised for issue on 24 September 2026 and are signed on their behalf by:

Tom Leader
Chair
Company Number 06397765

Statement of changes in equity

  Share
capital
£’000
Share premium £’000 Capital
redemption
reserve
£’000
Special distributable reserve1
£’000 
Capital
reserve realised1
£’000 
Capital
reserve unrealised
£’000 
Revenue reserve1
£’000 
Total 
£’000 
As at 1 January 2026 1,648 256 141 1,048,301  (241,857) (33,239) (42,406) 732,844 
Comprehensive income for the period:                
Management fees allocated as capital expenditure – – – –  (5,706) –  –  (5,706)
Current year gain on disposal of fixed asset investments – – – –  7,077  –  –  7,077 
Current year gain on disposal of current asset investments – – – –  5  –  –  5 
Gain on fair value of fixed asset investments – – – –  –  7,245  –  7,245 
Loss on fair value of current asset investments – – – –  –  (440) –  (440)
Profit after tax – – – –  –  –  1,483  1,483 
Foreign exchange translation – – – –  –  –  (1) (1)
Total comprehensive income for the period – – – –  1,376  6,805  1,482  9,663 
Contributions by and distributions to owners:                
Share issue2 – 219 – –  –  –  –  219 
Total contributions by and distributions to owners – 219 – – –  –  –  219 
Other movements:                
Prior year fixed asset gains now realised – – – –  18,305  (18,305) –  – 
Prior year current asset gains now realised – – – –  1,065  (1,065) –  – 
Total other movements – – – –  19,370  (19,370) –  – 
Balance as at 30 June 2026 1,648 475 141 1,048,301  (221,111) (45,804) (40,924) 742,726 

1. Included within these reserves is an amount of £740,462,000 which is considered distributable to shareholders under Companies Act rules. The Income Taxes Act 2007 restricts distribution of capital from reserves created by the conversion of the share premium account into a special distributable reserve until the third anniversary of the share allotment that led to the creation of that part of the share premium account. As at 30 June 2026, £764,229,000 of the special reserve is distributable under this restriction.

2. During the period, 491,661 shares were issued in connection with the client rebate allotment.

The accompanying notes form an integral part of the financial statements.

  Share
capital
£’000
Share premium £’000 Capital
redemption
reserve
£’000
Special distributable reserve1
£’000 
Capital
reserve realised1
£’000 
Capital
reserve unrealised
£’000 
Revenue reserve1
£’000 
Total 
£’000 
As at 1 January 2025 1,647 – 141 1,056,537  (125,444) (57,285) (44,238) 831,358 
Comprehensive income for the period:                
Management fees allocated as capital expenditure – – – –  (7,838) –  –  (7,838)
Current year gain on disposal of fixed asset investments – – – –  1,184  –  –  1,184 
Current year gain on disposal of current asset investments – – – –  105  –  –  105 
Loss on fair value of fixed asset investments – – – –  –  (29,593) –  (29,593)
Gain on fair value of current asset investments – – – –  –  1,450  –  1,450 
Loss after tax – – – –  –  –  (2,234) (2,234)
Foreign exchange translation – – – –  –  –  42  42 
Total comprehensive income for the period – – – –  (6,549) (28,143) (2,192) (36,884)
Contributions by and distributions to owners:                
Share issue 1 256 – –  –  –  –  257 
Dividends paid – – – (8,236) –  –  –  (8,236)
Total contributions by and distributions to owners 1 256 – (8,236) –  –  –  (7,979)
Other movements:                
Prior year fixed asset losses now realised – – – –  (18,048) 18,048  –  – 
Prior year current asset gains now realised – – – –  336  (336) –  – 
Total other movements – – – –  (17,712) 17,712  –  – 
Balance as at 30 June 2025 1,648 256 141 1,048,301  (149,705) (67,716) (46,430) 786,495 

1. Included within these reserves is an amount of £784,450,000 which is considered distributable to shareholders under Companies Act rules. The Income Taxes Act 2007 restricts distribution of capital from reserves created by the conversion of the share premium account into a special distributable reserve until the third anniversary of the share allotment that led to the creation of that part of the share premium account. As at 30 June 2025, £656,897,000 of the special reserve is distributable under this restriction.

The accompanying notes form an integral part of the financial statements.

  Share
capital
£’000 
Share
premium
£’000 
Capital redemption reserve 
£’000 
Special distributable reserve1
£’000 
Capital reserve realised1
£’000 
Capital reserve unrealised 
£’000 
Revenue
reserve1
£’000 
Total 
£’000 
As at 1 January 2025 1,647  –  141  1,056,537  (125,444) (57,285) (44,238) 831,358 
Comprehensive income for the year:                
Management fees allocated as capital expenditure –  –  –  –  (14,253) –  –  (14,253)
Current year loss on disposal of fixed asset investments –  –  –  –  (5,227) –  –  (5,227)
Current year loss on disposal of current asset investments –  –  –  –  (15) –  –  (15)
Loss on fair value of fixed asset investments –  –  –  –  –  (72,727) –  (72,727)
Loss on fair value of current asset investments –  –  –  –  –  (145) –  (145)
Gain after tax –  –  –  –  –  –  1,860   1,860 
Foreign exchange translation –  –  –  –  –  –  (28) (28)
Total comprehensive income for the year –  –  –  –  (19,495) (72,872) 1,832  (90,535)
Contributions by and distributions to owners:                
Share issue (includes DRIS)2 1  256  –  –  –  –  –  257 
Share issue costs –  –  –  –  –  –  –  – 
Repurchase of own shares –  –  –  –  –  –  –  – 
Dividends paid (includes DRIS)2 –  –  –  (8,236) –  –  –  (8,236)
Total contributions by and distributions to owners 1  256  –  (8,236) –  –  –  (7,979)
Other movements:                
Share premium cancellation –  –  –  –  –  –  –  – 
Prior year fixed asset losses now realised –  –  –  –  (53,999) 53,999  –  – 
Prior year current asset gains now realised –  –  –  –  581  (581) –  – 
Transfer between reserves –  –  –  –  (43,500) 43,500  –  – 
Total other movements –  –  –  –  (96,918) 96,918  –  – 
Balance as at 31 December 2025 1,648  256  141  1,048,301  (241,857) (33,239) (42,406) 732,844 

1. Included within these reserves is an amount of £730,799,000 (2024: £829,571,000) which is considered distributable to shareholders under Companies Act rules. The Income Taxes Act 2007 restricts distribution of capital from reserves created by the conversion of the share premium account into a special distributable reserve until the third anniversary of the share allotment that led to the creation of that part of the share premium account. As at 31 December 2025, £656,897,000 (2024: £375,740,000) of the special reserve is distributable under this restriction.

2. The Company did not operate any DRIS during the year ended 31 December 2025.

The accompanying notes form an integral part of the financial statements.

Cash flow statement

  Unaudited
Six months to
30 June
2026 

Unaudited
Six months to 
30 June 
2025 

Audited
Year to
31 December
2025 

 
 
 
  £’000  £’000  £’000 
Reconciliation of loss to cash flows from operating activities      
Profit/(loss) before tax 9,663  (36,884) (90,535)
Decrease/(increase) in debtors 116  3  (986)
Decrease in creditors (700) (1,044) (591)
(Gain)/loss on disposal of current asset investments (5) (105) 15 
Loss/(gain) on valuation of current asset investments 440  (1,450) 145 
(Gain)/loss on disposal of fixed asset investments (7,077) (1,184) 5,227 
(Gain)/loss on valuation of fixed asset investments (7,245) 29,593  72,727 
Outflow from operating activities (4,808) (11,071) (13,998)
Cash flows from investing activities      
Sale of current asset investments1 23,993  7,233  12,277 
Purchase of fixed asset investments (3,917) (8,176) (14,722)
Proceeds from sale of fixed asset investments 45,549  2,503  6,510 
Inflow from investing activities 65,625  1,561  4,065 
Cash flows from financing activities      
Movement in applications account 2  (4) (4)
Dividends paid (net of DRIS) –  (8,236) (8,236)
Purchase of own shares –  –  – 
Share issues (net of DRIS) 219  257  257 
Share issues costs –  –  – 
Inflow/(outflow) from financing activities 221  (7,983) (7,983)
Increase/(decrease) in cash and cash equivalents 61,038  (17,494) (17,916)
Opening cash and cash equivalents 75,842  93,758  93,758 
Closing cash and cash equivalents 136,881  76,264  75,842 
Cash and cash equivalents comprise      
Cash at bank 2,232  918  806 
Applications cash 20  18  18 
Money market funds 134,629  75,328  75,018 
Closing cash and cash equivalents 136,881  76,264  75,842 

1. Proceeds from the sale of current asset investments principally relate to the realisation of corporate bond holdings as investments matured during the period.
The accompanying notes form an integral part of the financial statements.

Condensed notes to the financial statements

1. Basis of preparation

The unaudited half-yearly results for the six months ended 30 June 2026 have been prepared in accordance with the Financial Reporting Council’s (FRC) Financial Reporting Standard 104 Interim Financial Reporting (January 2022) and the Statement of Recommended Practice (SORP) for Investment Companies re-issued by the Association of Investment Companies in July 2022.

2. Publication of non-statutory accounts

The unaudited half-yearly results for the six months ended 30 June 2026 do not constitute statutory accounts within the meaning of Section 415 of the Companies Act 2006 and have not been delivered to the Registrar of Companies. The comparative figures for the year ended 31 December 2025 have been extracted from the audited financial statements for that year, which have been delivered to the Registrar of Companies. The independent auditor’s report on those financial statements, in accordance with Chapter 3, Part 16 of the Companies Act 2006, was unqualified. This half-yearly report has not been reviewed by the Company’s auditor.

3. Earnings per share

The profit per share is based on 1,647,807,550 Ordinary shares (30 June 2025: 1,647,303,176 and 31 December 2025: 1,647,516,355), being the weighted average number of shares in issue during the period. There are no potentially dilutive capital instruments in issue and so no diluted returns per share figures are relevant. The basic and diluted earnings per share are therefore identical.

4. Net asset value per share

  30 June 30 June 31 December
  2026 2025 2025
Net assets (£’000) 742,726 786,495 732,844
Ordinary shares in issue 1,648,217,720 1,647,726,059 1,647,726,059
Net asset value per share 45.1p 47.7p 44.5p

5. Dividends

No dividend was declared in respect of the year ended 31 December 2025, and no dividend was paid during the six months ended 30 June 2026.

6. Buybacks and allotments

During the six months to 30 June 2026, the Company did not repurchase any Ordinary shares (six months ended 30 June 2025: the Company did not repurchase any Ordinary shares; year ended 31 December 2025: the Company did not repurchase any Ordinary shares).

During the six months to 30 June 2026, 491,661 shares were issued in connection with the client rebate allotment at a weighted average price of 44.5p per share (six months ended 30 June 2025: 513,704 shares at a weighted average price of 50.0p per share; year ended 31 December 2025: 513,704 shares were issued at an average price of 50.0p per share).

7. Transactions with the Manager and Portfolio Manager

Octopus AIF Management Limited acts as the Manager of the Company and has appointed Octopus Investments Limited to act as Portfolio Manager, responsible for portfolio management and the day-to-day running of the Company.

On 11 September 2025, the Company entered into a new investment management and non-investment services agreement (the IMNISA) with the Manager and Portfolio Manager, replacing the previous separate investment management and non-investment services arrangements. Under the previous arrangements, the Company paid an annual management charge of 2% of NAV together with a separate fee for non-investment services.

Under the IMNISA, Octopus provides investment management services together with financial, company secretarial and product management non‑investment services to the Company, in return for a single combined management fee.

Under the IMNISA, Octopus AIF Management Limited and Octopus Investments Limited are together entitled, in aggregate, to a management fee of 2% per annum of the Company’s NAV, payable quarterly in advance and calculated using the latest published NAV of the Company and the number of shares in issue at each quarter end. The management fee is subject to tiering, reducing to 1.75% where NAV is between £500 million and £750 million, and to 1.4% where NAV exceeds £750 million. The management fee is also reduced where the Company’s uninvested cash exceeds 10% of NAV and the overall actual percentage rate charged on that excess amount exceeds the average total return on that uninvested cash.

During the period, the Company incurred management fees of £6,006,000 payable to Octopus (30 June 2025: £8,251,000 investment management fees and £1,067,000 non-investment services fees under the previous fee arrangements; 31 December 2025: £15,003,000 total investment management and non-investment services fees under the new agreement).

During a transitional period following the implementation of the IMNISA (the ‘Transition Period’), the Manager will rebate up to 20% of the management fee back to the Company where certain performance and realisation targets are not achieved. Accordingly, during the period an accrued rebate of £977,000 (31 December 2025: £913,000) was recognised in respect of the period from 1 January 2026 to 30 June 2026.

Under the IMNISA, the Manager is entitled to a performance-related incentive fee in respect of accounting periods commencing on or after 1 January 2034. No performance-related fees were accrued for the six months to 30 June 2026 (30 June 2025: £nil; 31 December 2025: £nil).

Octopus received £0.02 million in the period to 30 June 2026 (30 June 2025: £0.01 million; 31 December 2025: £0.02 million) in regard to arrangement and monitoring fees in relation to investments made on behalf of Titan. Since 31 October 2018, Octopus no longer receives such fees in respect of new investments or any such new fees in respect of further investments into portfolio companies in which Titan invested on or before 31 October 2018, with any such fees received after that time being passed to Titan.

8. Related party transactions
Titan owns Zenith Holding Company Limited, which owns a share in Zenith LP, a fund managed by Octopus.

Several members of the Octopus investment team hold non-executive directorships as part of their monitoring roles in Titan’s portfolio companies, but they have no controlling interests in those companies.

The Directors received the following dividends from Titan:

  Period to Period to Year to
  30 June 30 June 31 December
  20262 2025 2025
Jane O’Riordan1 – 779 573
Tom Leader (Chair) – 241 241
Lord Rockley – 395 395
Gaenor Bagley – 121 121
Julie Nahid Rahman – 22 22
Rupert Dickinson – – –

1. Jane O’Riordan retired as a Director on 4 December 2025.
2. No dividends were paid during the six months ended 30 June 2026.

9. Voting rights and equity management

The following table shows the percentage voting rights held by Titan of each of the top ten investments held in Titan, on a fully diluted basis.

  % equity
Investments held by Titan
Mr & Mrs Oliver Ltd (trading as Skin + Me) 20.6%
Digital Therapeutics (trading as Pelago, formerly Quit Genius) 14.0%
Elliptic Enterprises Limited 5.8%
vHive Tech Limited 19.0%
Many Group Limited (trading as Many Pets) 7.5%
Vitesse PSP Limited 9.8%
Amplience Limited 21.3%
Permutive Inc. 17.2%
The Justice Platform Inc. (trading as Legl) 20.1%
Token 13.3%

10. Post balance sheet events
The following events occurred between the balance sheet date and the signing of this half‑yearly report:

  • the Company received £2.5 million in disposal and deferred consideration proceeds; and
  • the Company declared an interim dividend of 1.0p to be paid on 18 December 2026.

11. Half-Yearly Report
The unaudited half-yearly report for the six months ended 30 June 2026 will shortly be available to view at https://octopusinvestments.com/our-products/venture-capital-trusts/octopus-titan-vct/

A copy of the report will be submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information please contact:

Rachel Peat  
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800A67IKGG6PVYW75

LONDON and PHILADELPHIA, Sept. 25, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, the “Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation of the FOCUS-01 trial design and preclinical data highlighting the potential of AVA6103 (FAP-Exd) in pancreatic ductal adenocarcinoma (PDAC).  FOCUS-01 is the Phase 1 trial of AVA6103, the Company’s first Next-Generation pre|CISION® peptide-drug conjugate (PDC) and is being presented at the American Association for Cancer Research (“AACR”) Conference on Pancreatic Cancer in San Diego, California, held between 25-28 September 2026.

The presentation highlights the design of the FOCUS-01 Phase 1 study of AVA6103 and updated preclinical data supporting the assessment of AVA6103 in patients with PDAC. AVA6103 is designed to significantly increase the therapeutic window of the highly potent payload, exatecan, and the trial implements a dose-dense arm, dosing every two weeks (Q2W), to enhance the delivery of payload to the tumor over traditional dosing of ADCs at every three weeks (Q3W).  Preclinical studies using the dose-dense regimen in patient-derived xenograft (PDX) mouse models of PDAC demonstrate that AVA6103 achieved tumor-targeted delivery of exatecan with highly durable complete and partial responses in multiple models observed for weeks following cessation of dosing.

Additionally, researchers observed high FAP expression in PDAC with close proximity of FAP-expressing cancer-associated fibroblasts (CAFs) to both blood vessels and tumor cells, shown via multiplex immunofluorescence (mIF). These findings support the mechanism of action of the Next Gen pre|CISION medicines: efficient PDC delivery to the tumor, cleavage and release of payload with tumor cell uptake of released payload.

Christina Coughlin, CEO of Avacta, commented:

“The preclinical data presented at AACR underscore the significant potential of AVA6103 in addressing the challenges of pancreatic cancer, a disease with limited treatment options and poor prognosis. The robust preclinical efficacy, combined with the high FAP expression in PDAC, further strengthens our confidence in AVA6103 as a promising therapeutic candidate to improve treatment options for patients.

“This adds to the momentum of AVA6103 and highlights the potential of our unique pre|CISION® technology to bring hope to patients battling PDAC and other aggressive cancers. The first clinical data from the FOCUS-01 trial, providing clinical evidence consistent with tumor-specific delivery of exatecan by AVA6103, have further reinforced our confidence in this program and we are now moving towards an initial efficacy readout from the study in H1 2027.”

FOCUS-01: Trial in Progress

The FOCUS-01 Phase 1a trial is a first in-human, multicenter dose escalation trial of AVA6103 and is enrolling patients with select tumor types predicted to be sensitive to the payload exatecan, including PDAC. Patients with PDAC are enrolled in the Q2W dosing arm, a dose-intense regimen designed to match standard of care in the indication. The ability to deliver dose intensity and flexible administration is unique to pre|CISION® Next-Gen PDCs because:

  • In contrast to antibodies, the pre|CISION® peptide does not accumulate, enabling more frequent dosing when appropriate; and
  • The pre|CISION® Next-Gen mechanism retains and cleaves the conjugate inside the tumor, significantly limiting systemic exposure to the payload and enabling the interval between doses to be shortened, allowing delivery of higher dose intensity compared to ADCs.

Preliminary safety and pharmacokinetic (PK) data from the first three dose levels of the FOCUS-01 trial, reported earlier this month, demonstrated proof of mechanism in patients treated in the first three cohorts in the trial. AVA6103 demonstrated a favorable safety profile and was well tolerated through the first three dose levels up to a payload dose approximately 50% higher than the maximum tolerated dose (MTD) of conventional exatecan.

The pharmacokinetic data of the PDC, released peptide and released exatecan patients were remarkably consistent with predictive PK modelling based on preclinical data, greatly increasing confidence that the safety profile, tumor selectivity and antitumor efficacy observed in the preclinical studies of AVA6103 will translate into the clinic.

Enrollment is ongoing in both arms of the study with patients treated at dose level 4, which represents an absolute dose of payload that is more than double the MTD of conventional exatecan and approaches the equivalent topoisomerase I inhibitor payload dose of the approved dose of Enhertu® in breast cancer.

Details of the poster presentation

Title:  A Phase I Trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION® Peptide-drug Conjugate Delivering Sustained Tumor Microenvironment (TME) Release of Exatecan in Patients with FAP-positive Solid Tumors

First Author: Alex Spira, MD

Session: New Frontiers in Biology and Therapeutic Development

Date: September 26, 2026

Enhertu® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Enhertu® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

For further information from Avacta, please contact:

Avacta Group plc
Christina Coughlin, Chief Executive Officer
https://avacta.com/
via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser)
James Harris / Chris Raggett / James Dance 
 
www.strandhanson.co.uk
 
Zeus (Broker)
James Hornigold / George Duxberry / Dominic King 
 
www.zeuscapital.co.uk
Cohesion Bureau
Communications / Media / Investors
Chris Maggos
 
avacta@cohesionbureau.com
 

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.

About AVA6103 (FAP-Exd)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (F AP-Exd in O ncologic C ancers with U nmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

DIVERSIFIED ENERGY COMPANY

(“Diversified”, or the “Company”)

DIVERSIFIED ENERGY COMPANY (NYSE:DEC; LSE:DEC) announces that, in accordance with the terms of its share buyback program announced on March 20, 2025, the Company has purchased 80,000 shares of common stock, par value $0.01 per share of the Company (the “Shares”) in the market at a volume-weighted average price of $13.9561 per Share through Mizuho Securities USA LLC (MSUSA). The Shares acquired will, in due course, be cancelled.

Aggregated Information

Date of Purchase: September 24, 2026
Aggregate Number of Shares Purchased: 80,000
Lowest Price Paid per Share (USD): $13.80
Highest Price Paid per Share (USD): $14.015
Volume-Weighted Average Price Paid per Share (USD): $13.9561
   

Following the cancellation of Shares, Diversified will have 70,699,231 shares of common stock, in issue and no shares of common stock is held in treasury. This figure of 70,699,231 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), the table below contains detailed information of the individual trades made by Mizuho Securities USA LLC as part of the buyback program.

Schedule of Purchases

Aggregate number of ordinary shares acquired Daily volume weighted average price paid Daily highest price paid per share Daily lowest price per share Trading Venue
4728 13.9652 $14.01 $13.84 ARCX
6007 13.9847 $14.01 $13.91 ASPN
500 14.0100 $14.01 $14.01 BAML
215 13.9700 $14.01 $13.90 BATS
1000 13.9527 $14.01 $13.82 BATY
300 13.9667 $14.00 $13.91 EDGA
3666 13.9847 $14.01 $13.82 EDGX
50128 13.9417 $14.02 $13.80 IEXG
741 13.9744 $14.01 $13.89 JPMX
36 13.9900 $13.99 $13.99 MEMX
500 13.9960 $14.00 $13.98 SGMT
2236 13.9833 $14.01 $13.84 UBSA
800 13.9538 $14.01 $13.84 XBOS
100 13.8200 $13.82 $13.82 XCIS
5366 13.9784 $14.01 $13.84 XNAS
3677 13.9796 $14.01 $13.84 XNYS
Trading venue Currency      
NYSE USD $13.9561 80,000  


For further information, please contact:

Diversified Energy Company +1 973 856 2757
Doug Kris dkris@dgoc.com
Senior Vice President, Investor Relations & Corporate Communications www.div.energy
   

About Diversified Energy Company

Diversified is a leading publicly traded energy company focused on acquiring, operating, and optimizing cash generating energy assets. Through our differentiated strategy, we acquire existing, long-life assets and invest in them to improve environmental and operational performance until retiring those assets in a safe and environmentally secure manner. Recognized by ratings agencies and organizations for our sustainability leadership, this solutions-oriented, stewardship approach makes Diversified the Right Company at the Right Time to responsibly produce energy, deliver reliable free cash flow, and generate shareholder value.

From Saltwater Immersion to Underbody Scraping, Real Technology Stands Up to Transparent Testing

CONSTANȚA, Romania, Sept. 25, 2026 (GLOBE NEWSWIRE) — From September 22 to 24, Constanța, a coastal city on Romania’s Black Sea coast, welcomed more than 150 media representatives from 16 European countries to witness the CHERY CSH Global Safety Challenge in Europe. At CHERY’s invitation, media and technical experts came together to observe the safety tests in an open and transparent setting.

Two consecutive engineering safety tests addressed Safety concerns through on-site testing and measurable results

On the evening of September 22, the 34.46 kWh high-voltage battery from the TIGGO9 CSH was removed from the vehicle on site and fully immersed in a 3.5% NaCl saltwater solution. After 24 hours, the test was completed. Engineers inspected the battery enclosure, connectors and pressure relief valve, followed by checks of its airtightness and insulation performance. The results showed no visible signs of corrosion, swelling or leakage, while no traces of water were found inside the connectors. The measured leakage rate was 8.067 Pa/min, while insulation resistance remained above 500 MΩ, both meeting the test criteria.

Following reinstallation of the battery, the vehicle operated normally, paving the way for the second challenge — the underbody scraping test. Designed to simulate situations in which the vehicle underbody encounters road obstacles or sudden changes in road level, the TIGGO9 CSH drove over a 250 mm-high step obstacle at 14–15 km/h. Engineers then inspected the vehicle underbody and battery enclosure. While scratches were found on the PVC coating of the underbody protection plate, no structural damage or cracking was found on the battery enclosure. No electrolyte leakage was detected, the relevant connectors and cooling circuits showed no abnormalities, and no safety warning appeared on the vehicle dashboard.

With European journalists and German technical experts observing the process, both tests were successfully completed, with the results demonstrating that the TIGGO9 CSH battery maintained its structural condition and normal functionality after exposure to two different forms of stress: prolonged saltwater immersion and physical impact from underneath the vehicle.

The TIGGO Family Takes to the Road, with a 19-Vehicle Convoy Exploring the Black Sea Coast

On the morning of September 23, a 19-vehicle TIGGO convoy set out from Mamaia Beach in Constanța. The route followed Lake Siutghiol and the Black Sea coast towards Corbu Beach before turning inland, passing through the limestone landscapes of Cheile Dobrogei and the Gura Dobrogei Nature Reserve, before returning to Mamaia via Mihail Kogălniceanu and Ovidiu.

1

(Test drive ceremony)

From coastline and lakes to limestone gorges and open countryside, the route brought together the diverse landscapes of the Dobrogea region while offering a variety of European road environments. The TIGGO4, TIGGO7, TIGGO8 and TIGGO9 travelled the route together, giving media and guests an opportunity to experience the vehicles from behind the wheel.

The road drive brought CHERY’s technology back into everyday driving conditions — from engineering testing to the road, from technology to users, and ultimately to the everyday journeys of families.

From Every Journey to Every Family

From the Black Sea coast to the heart of Dobrogea, and from engineering testing to everyday road experience, CHERY remains focused on how technology can ultimately serve every family’s mobility needs.

As the Chinese Mid-Autumn Festival approaches, family and togetherness sharing the same core for this journey. For CHERY, safety is not only a continuous engineering challenge, but also a responsibility to protect every journey and every moment that brings families together.

As the moon shines over the sea, bringing people together across distances, CHERY’s commitment to family mobility will continue from Europe to the rest of the world. In October, CHERY will host its 2026 Chery International User Summit in Wuhu, China, bringing together users from around the world to share their journeys and explore closer connections between people, vehicles and the brand.

From a single safety challenge to every journey that follows, CHERY remains committed to using technology to protect mobility and putting users at the centre — helping make every journey more confident and reassuring.

Safety. For Family.

Contact: Sylvie Zhang
Company Name: Chery Automobile Co., Ltd. Europe Region
Website: https://www.cheryinternational.com
Email: zhangxinrui2@mychery.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f73b28ce-cc48-452d-bd28-001f15e57e69

Sampo plc, stock exchange release, 25 September 2026 at 8:40 am EEST

Sampo completes its share buyback programme

Sampo plc has completed its EUR 350 million share buyback programme, launched on 6 May 2026. The repurchases of shares began on 7 May 2026 and ended on 24 September 2026. During that period, Sampo repurchased 37,827,020 of its own A shares at an average price of EUR 9.24 per share. This corresponds to 1.42 per cent of all Sampo plc’s shares based on the share count prior to the start of this programme. The repurchase of own shares has reduced the company’s unrestricted equity by approximately EUR 350 million.

The purpose of the buyback programme was to return excess capital to shareholders by reducing Sampo plc’s capital, as the repurchased shares will be cancelled. Following the cancellation, the total number of Sampo shares will be 2,617,847,806 shares, of which 2,616,847,806 will be A shares and 1,000,000 B shares.

Further information on share buybacks is available at www.sampo.com/sharebuyback.

SAMPO PLC
Investor Relations and Group Communications


For further information, please contact:

Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032

Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com

Sampo plc, stock exchange release, 25 September 2026 at 8:30 am EEST

Sampo plc’s share buybacks week 39/2026

During week 39 (21 September 2026 – 24 September 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:

Market
(MIC Code)
Daily volume (in number of shares) and weighted average price of the purchased shares, EUR* Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*
    21/09/2026 22/09/2026 23/09/2026 24/09/2026 Week 39/2026, total
AQEU Volume 3,741 31,734 88,662 77,430 201,567
Average price 9.42 9.38 8.87 8.77 8.92
CEUX Volume 55,404 278,332 290,402 353,954 978,092
Average price 9.41 9.35 9.00 8.76 9.03
TQEX Volume 17,664 38,016 41,230 64,359 161,269
Average price 9.41 9.30 9.00 8.76 9.02
XHEL Volume 46,461 653,476 826,661 1,399,257 2,925,855
Average price 9.40 9.36 8.90 8.77 8.95
XOFF Volume 0 0 781,436 0 781,436
Average price 0 0 9.00 0 9.00
Total, all markets Volume 123,270 1,001,558 2,028,391 1,895,000 5,048,219
Average price 9.41 9.35 8.95 8.77 8.97

* rounded to two decimals

In addition to shares repurchased in public trading during week 39, Sampo has, through its lead manager Morgan Stanley Co. International plc, repurchased 781,436 of its own A shares (FI4000552500) in the accelerated bookbuild announced by Solidium Oy on 22 September 2026. Sampo’s lead manager carried out the repurchase of the shares on Sampo’s behalf under the share buyback programme that started on 7 May 2026. The price per share was EUR 9.00 and the total acquisition price amounts to EUR 7,032,924.

On 6 May 2026, Sampo announced a share buyback programme of up to a maximum of EUR 350 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 7 May 2026, is based on the authorisation granted by Sampo’s Annual General Meeting on 22 April 2026.

After the disclosed transactions, the company owns in total 37,827,020 Sampo A shares representing 1.42 per cent of the total number of shares in Sampo plc.

Details of each transaction are included as an appendix of this announcement.

On behalf of Sampo plc,
Morgan Stanley Co. International plc

For further information, please contact:

Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032

Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com

Attachment

  • The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle Liebschutz
  • A leadership team covering the entire value chain: pharmaceutical development, industrial operations, quality and regulatory affairs, finance and corporate
  • CROSSJECT US strengthens its regulatory leadership with the appointment of David Pudwill as Vice President, Regulatory & Scientific Affairs

DIJON, FRANCE, September 25, 2026 – 07h30 (CEST) – CROSSJECT (ISIN: FR0011716265; Euronext Growth: ALCJ), a Specialty Pharma company developing innovative solutions for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, today announces that its Supervisory Board, meeting on September 24, 2026, unanimously appointed Olivier Lacombe, Didier Morin and Lionel Seltz as members of the Executive Board. Their appointments are effective immediately, and their terms will expire on February 17, 2029.

“In 2025, the Board streamlined the Executive Board around a single priority: the registration of ZEPIZURE®. The priority now is to industrialise and deliver. We are therefore expanding the Executive Board so that the key skills for this new phase are represented where decisions are made. Drawn from the existing team, these three appointments give CROSSJECT a complete, experienced and immediately operational leadership,” said Philippe Monnot, Chairman of the Supervisory Board.

The Executive Board of CROSSJECT now comprises Patrick Alexandre, Chairman, Isabelle Liebschutz, Quality and Regulatory Director and Qualified Person, Olivier Lacombe, Pharmaceutical Development Director, Didier Morin, Industrial Director, and Lionel Seltz, Chief Financial Officer. The three new members continue to exercise their current operational responsibilities.

A governance structure built for the execution phase

In February 2025, the Supervisory Board narrowed the Executive Board to two members in order to focus decision-making on the final stages of ZEPIZURE®’s registration with the FDA (U.S. Food and Drug Administration). As that work advances, CROSSJECT is preparing for a phase of a different nature: scaling up its industrial operations, preparing initial deliveries and building its commercial presence in the United States.

This phase simultaneously mobilises pharmaceutical development, manufacturing and supply chain, regulatory compliance and the Group’s financial structure. The expansion of the Executive Board responds directly to that shift: every critical link, from the molecule to delivery to the patient, is now represented within the body that leads the Company. It also reflects the structuring of the Group around its French and U.S. entities.

The Executive Board now brings together 140 years of combined experience in pharmaceuticals, medical devices and industrial operations.

Olivier Lacombe, Pharmaceutical Development Director, joined CROSSJECT in 2021. He brings 21 years of experience in pharmaceutical development, gained notably at Laboratoires FOURNIER, ABBOTT, SOLVAY and INVENTIVA. He leads the pharmaceutical development of the ZENEO® platform and the pharmaceutical quality documentation of the product portfolio.

Didier Morin, Industrial Director, joined CROSSJECT in 2023. He brings 30 years of industrial experience, gained notably at IDS and AXESS VISION. He leads the Group’s industrial operations, the scale-up of its production sites and its supply chain.

Lionel Seltz, Chief Financial Officer, joined CROSSJECT in January 2026. He brings 25 years of international financial experience in life sciences and healthcare, gained at CEGEDIM, at IQVIA/IMS Health in Asia-Pacific and within the MARS GROUP, as well as serving as Chief Financial Officer of three listed medtech and biotech companies. His remit covers finance and treasury, financial communication, legal and governance, intellectual property, U.S. government contracts, human resources and information systems.

CROSSJECT US strengthens its regulatory leadership

Alongside the strengthening of its governance, CROSSJECT continues to build its U.S. organisation.
David Pudwill has joined CROSSJECT US as Vice President, Regulatory & Scientific Affairs, and reports to Tony Tipton, Chief Operating Officer of CROSSJECT US, who leads the U.S. entity’s operations and will support David in carrying out his regulatory and scientific responsibilities.

David Pudwill brings approximately 20 years of experience in regulatory affairs, product development, quality and clinical strategy, including nine years with the FDA (U.S. Food and Drug Administration), where he served as a lead medical device reviewer and as a branch chief. His experience spans medical devices, pharmaceuticals, biologics and drug-device combination products, with particular expertise in complex FDA pathways and cross-center programs. That profile maps directly onto the combination nature of the ZENEO® platform. He holds a Master of Mechanical Engineering from Johns Hopkins University and a Bachelor’s Degree in Biomedical Engineering from Case Western Reserve University.

At CROSSJECT US, David Pudwill leads the U.S. regulatory, clinical and scientific strategy for ZEPIZURE® and future products based on the ZENEO® platform. He supports the Company’s engagement with the FDA, BARDA and other U.S. government and strategic partners, and strengthens coordination between the French and U.S. teams.

“CROSSJECT is entering an important phase of execution as it scales manufacturing and prepares for commercialization of ZENEO-based products. I look forward to helping CROSSJECT continue to build its relationships with BARDA, the FDA and other strategic partners as it advances ZEPIZURE® through the FDA authorization process and prepares, subject to that authorization, to deliver product to the U.S. Strategic National Stockpile,” said David Pudwill, Vice President, Regulatory & Scientific Affairs, CROSSJECT US.

“CROSSJECT is changing in nature: we are moving from a development company to a company that manufactures, delivers and commercialises. The people who built ZENEO® and ZEPIZURE® are the ones who should lead its industrialisation and launch. By expanding the Executive Board and strengthening our regulatory team in the United States, we are giving ourselves the means to execute this transition with the rigour our partners expect, BARDA and the FDA first among them,” said Patrick Alexandre, Chairman of the Executive Board.

Attachment

Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May.

Shareholders’ equity returned to positive territory at €3.0 million (compared to −€4.9 million as of December 31, 2025), and adjusted net financial debt was more than halved to €7.8 million (from €17.4 million).

BARDA revenue totaled €2.5 million (€6.6 million in H1 2025), as H1 2025 saw a concentration of validation activities and a clinical trial; H1 2026 returned to a pace representative of ongoing development activity. Operating expenses remained stable at €10.3 million, excluding depreciation, provisions, and disposal-related items (€10.3 million in H1 2025).

Net income of −€8.6 million (−€4.9 million in H1 2025): H1 2025 saw two non-recurring milestones—the validation campaign and a clinical trial.

Post-closing: BARDA contract extended through 2030 and increased to $48.0 million (+$4.7 million in non-dilutive funding).

DIJON, France – September 25, 2026 (7:30 a.m. CEST) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free autoinjector technology, currently in the advanced stages of development and regulatory approval for ZEPIZURE®, an injectable treatment for epileptic seizures, today published its results for the first half of the year ended June 30, 2026.

Financial statements approved by the Executive Board on September 24, 2026, and reviewed by the Supervisory Board on September 24, 2026. These financial statements have not been subject to a limited review by the statutory auditors.

(in M€) H1 2026 H1 2025
Operating revenue 4.8 8.0
of which BARDA 2.5 6.6
Operating income −8.9 −5.1
Net income −8.6 −4.9
  06/30/26 12/31/25
Cash 12.3 5.1
Equity 3.0 −4.9
Adj. net financial debt 7.8 17.4

“The first half of 2026 was devoted to strengthening our financial foundations. The €15 million capital increase completed in May enabled us to return to positive equity and reduce our net debt by more than half. Our half-year results reflect a lower level of BARDA revenue compared to 2025, while our operating expenses remain under control. Alongside BARDA, our teams remain fully focused on the registration of ZEPIZURE® and on preparing our first shipments.”

Patrick ALEXANDRE, Chairman of the Executive Board of CROSSJECT

“Our priority is clear: to manage cash flow with the utmost rigor and to secure the Company’s financing—giving priority to non-dilutive resources—until ZEPIZURE® generates its first commercial revenue.”

Lionel SELTZ, Chief Financial Officer

Highlights of the First Half of 2026

A Significant Strengthening of Equity

On May 22, 2026, CROSSJECT completed a capital increase reserved for a specific category of investors, accompanied by an issuance of stock subscription warrants (BSA), for a total gross amount of €15 million: 6,441,300 new shares were issued at a price of €1.704, and 6,441,300 stock warrants were subscribed at a price of €0.626. Maxim Group LLC acted as the exclusive placement agent. If all stock warrants are exercised (four warrants entitling the holder to subscribe for five shares at a price of €2.68), the Company could receive an additional amount of up to €21.6 million.

During the half-year, €2.07 million in convertible bonds (HCM) were converted into shares, contributing to the reduction in bond debt. As of June 30, 2026, the share capital consists of 60,023,823 shares.

Debt Reduction Underway

The Company repaid €1.8 million in bank loans and €1.2 million in repayable advances during the half-year.

Regulatory and Industrial Progress on ZEPIZURE®

During the first half of the year, CROSSJECT continued, in close collaboration with BARDA, the regulatory work related to ZEPIZURE®. Discussions took place at a steady pace and at a high technical level, focusing in particular on the dossier documentation as well as the accompanying manufacturing and qualification elements. This work is actively ongoing. In accordance with the communication strategy agreed upon with its U.S. partner, the Company does not disclose the timeline for the authorization process, which is managed by BARDA. Following an inspection, the ANSM issued a new certificate of compliance with Good Manufacturing Practices for all pharmaceutical operations carried out by CROSSJECT. The company also maintains its ISO 13485 certification for all of its sites in France.

On the industrial front, the Company continued to prepare its production facilities and supply chain for the first deliveries: it continued the investments already underway at its sites, carried out equipment qualification work, and strengthened its manufacturing partnerships. These investments are reflected on the balance sheet as €3.9 million in assets under construction as of June 30, 2026.

Organization and Visibility with the Financial Community

CROSSJECT strengthened its management team with the appointment of Lionel SELTZ as Chief Financial Officer that joined in January 2026. Portzamparc (BNP Paribas Group) initiated coverage of the stock in February 2026: CROSSJECT is now covered by five research firms (Alpha Value, Invest Securities, Maxim Group, ODDO BHF, and Portzamparc).

Analysis of First-Half 2026 Results

Operating revenue totaled €4.8 million, compared with €8.0 million in the first half of 2025 (−40%). Revenue from the BARDA contract amounted to €2.5 million, compared with €6.6 million a year earlier. This difference is timing-related and primarily reflects the exceptional nature of the first half of 2025, which saw the completion of two major program milestones: the validation campaign and the conduct of a clinical study. These milestones had driven activity—and thus the expenses reimbursed by BARDA—well above the usual pace. In line with the program schedule, the first half of 2026 returned to a level representative of ongoing development activity, similar to that of the first half of 2024. BARDA-funded activity is expected to increase again as the program moves through its next milestones, with the contract’s performance period now extended to June 2030 under Modification 4. Capitalized production (development costs) totaled €1.2 million (€1.5 million). Other income (€1.3 million, compared with €0.1 million) includes €0.6 million in proceeds from the disposal of fixed assets related to the refinancing of industrial projects and €0.7 million in reversals of provisions, including €0.4 million related to inventory.

Operating expenses totaled €13.7 million, compared with €13.2 million (+4%). This increase stems primarily from the net book value of disposed fixed assets (€0.5 million), which was not present in the first half of 2025 and was offset by the corresponding proceeds from the disposal. Depreciation, amortization, and provisions remained stable at €2.9 million (€2.9 million). Excluding depreciation, amortization, and provisions, as well as disposal-related items, operating expenses totaled €10.3 million, unchanged from the first half of 2025 (€10.3 million): other purchases and external expenses decreased by 4% to €5.1 million, and personnel expenses remained stable at €4.0 million.

Operating income came in at −€8.9 million, compared to −€5.1 million in the first half of 2025. This change mainly reflects lower BARDA revenue following an exceptional first half of 2025. The financial result improved to −€0.9 million (−€1.1 million). After accounting for the research tax credit (€1.3 million, compared to €1.6 million), net income came in at −€8.6 million, compared to −€4.9 million in the first half of 2025.

A Significantly Strengthened Financial Structure

As of June 30, 2026, total assets amounted to €35.6 million, compared to €30.4 million as of December 31, 2025. Shareholders’ equity returned to positive territory at €3.0 million, compared to −€4.9 million as of December 31, 2025, driven by the May 2026 capital increase and bond conversions, net of the half-year loss. Equity, including conditional advances, stood at €6.5 million. For the record, equity amounted to −€1.1 million as of June 30, 2025.

Gross financial debt was reduced to €18.6 million, compared to €22.4 million as of December 31, 2025 (−€3.8 million): bond debt stood at €7.5 million (€9.6 million) and bank loans at €8.5 million (€10.2 million). Conditional advances totaled €3.5 million (€4.7 million). Taking into account cash and cash equivalents of €12.3 million, net financial debt amounted to €6.3 million, compared to €17.4 million as of December 31, 2025 (−64%).

Cash Position

Available cash totaled €12.3 million as of June 30, 2026, compared to €5.1 million as of December 31, 2025, and €6.3 million as of June 30, 2025.

Events After the Balance Sheet Date

• BARDA Contract – Amendment 4. Extension of the performance period through June 21, 2030, and additional non-dilutive funding of $4.7 million, bringing the total funding for the development of ZEPIZURE® to $48.0 million. The new scope includes a pediatric clinical trial and a supplementary validation campaign featuring extended stability studies, neither of which are prerequisites for filing the EUA application for the adult indication.

• Liquidity Agreement. Effective July 1, 2026, the liquidity agreement is being administered by Rothschild & Co Global Markets Solutions (Europe) SA, following an internal reorganization of the Rothschild & Co group, with no change to its terms.

• Governance. The Supervisory Board meeting of September 24, 2026, expanded the Executive Board—see the dedicated press release dated September 25, 2026.

Availability of the Half-Year Financial Report

The half-year financial report as of June 30, 2026, will be made available to the public no later than October 30, 2026, on the Company’s website (www.crossject.com), under the “Finance” section.

Forward-Looking Statements

This press release contains forward-looking statements based on assumptions that the Company believes to be reasonable. These statements are subject to risks and uncertainties, including regulatory, industry, and financing risks, many of which are beyond the Company’s control and could result in materially different outcomes. A description of these risks is included in the 2025 Annual Report, available on the Company’s website. These statements are valid only as of the date of this press release, and, unless required by law, the Company undertakes no obligation to update them. This press release was prepared in French and English; in the event of any discrepancy, the French version shall prevail.

Appendix 1 – Half-Year Income Statement (in thousands of euros)

  H1 2026 H1 2025 Change
Operating Revenue 4,798 8,038 −3,240
BARDA Billing 2,532 6,557 −4,025
Capitalized production 1,209 1,483 −274
Production in inventory −272 −96 −176
Other products 1,329 95 1,234
of which: reversals of provisions 744 10  
including proceeds from the sale of fixed assets 567 28  
Operating expenses −13,735 −13,178 −557
Purchases used −797 −587 −210
Other purchases and external expenses −5,138 −5,356 218
Personnel expenses −4,018 −4,048 30
Taxes and duties −144 −147 3
Depreciation, amortization, and provisions −2,870 −2,866 −4
of which: inventory write-downs −374 −236  
Other expenses −769 −173 −596
of which: net book value of disposed fixed assets −539 –  
Operating income −8,938 −5,139 −3,799
Financial income −913 −1,143 230
Extraordinary income – −141 141
Research tax credit 1,275 1,555 −280
Net income −8,576 −4,869 −3,707

Appendix 2 – Balance Sheet (in thousands of euros)

  June 30, 2026 12/31/2025 Change
Fixed assets
Research and development expenses 7,256 8,086 −830
Licenses, patents, trademarks, and software 156 0 156
Property, plant, and equipment 2,173 2,429 −256
Assets under construction 3,870 3,487 383
Financial assets 1,158 998 160
Total fixed assets 14,613 15,000 −387
Current assets
Inventories and work in progress 4,088 3,493 595
Trade receivables and related accounts 975 1,975 −1,000
Other receivables (2) 2,893 3,918 −1,025
Cash and cash equivalents 12,345 5,080 7,265
Prepaid and deferred expenses 675 966 −291
Total Current Assets 20,976 15,433 5,543
Total assets 35,589 30,433 5,156

(2) Including advances and prepayments, tax receivables (research tax credit, VAT), and receivables from the sale of fixed assets. The balance sheet is compared to December 31, 2025, the date of the most recent annual financial statements.

Appendix 3 – Balance Sheet Liabilities (in thousands of euros)

  June 30, 2026 12/31/2025 Change
Shareholders’ Equity
Capital 6,002 5,225 777
Share premium 15,926 7,768 8,158
Retained earnings −11,259 −8,391 −2,868
Net income for the period −8,576 −10,368 1,792
Capital grants 882 892 −10
Total equity 2,976 −4,874 7,850
Conditional advances 3,505 4,688 −1,183
Provisions for risks and expenses 1,332 1,607 −275
Loans and debt
Bond issues (convertible and straight) 7,538 9,608 −2,070
Loans from credit institutions 8,450 10,211 −1,761
Miscellaneous loans and financial liabilities 2,629 2,629 0
Accounts payable 5,459 4,401 1,058
Tax and social security liabilities 1,636 1,602 33
Other liabilities 1,533 1 1,532
Deferred revenue 532 560 −28
Total Liabilities 27,776 29,011 −1,235
Total equity and liabilities 35,589 30,433 5,156

Appendix 4 – Net Financial Debt and Adjusted Net Financial Debt (in thousands of euros)

  June 30, 2026 12/31/2025 Change
Bond issues 7,538 9,608 −2,070
Bank loans 8,450 10,211 −1,761
Other financial liabilities 2,629 2,629 0
Gross financial debt 18,617 22,448 −3,831
Cash and cash equivalents −12,345 −5,080 −7,265
Net financial debt 6,272 17,367 −11,095
Amount to be repaid (2025 research tax credit pre-financing) (3) 1,532 – 1,532
Adjusted net financial debt 7,804 17,367 −9,563
Conditional advances 3,505 4,688 −1,183
Adjusted net debt including conditional advances 11,309 22,055 −10,746

Semiannual financial statements that have not been subject to a limited review by the auditors. Amounts rounded to the nearest thousand euros: some totals may not correspond exactly to the sum of their components.

 

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.